Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lumitrace and MediBeacon tGFR System in Heart Failure
NCT07349797Recruiting
- Sponsor
- MediBeacon
- Start
- Aug 2026
- Primary completion
- Jan 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of relmapirazin, sponsored by MediBeacon. Primary endpoint: Correlation of Transdermal Derived Glomerular Filtration Rate (tGFR) to the Plasma-derived Indexed Glomerular Filtration Rate (nGFR) at Day 1. Started Aug 2026; status: recruiting.
02
Drugs
relmapirazin
Beyond the preview
Go deeper on NCT07349797.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07349797.